Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
Intralesional bacillus Calmette–Guérin (BCG) followed by ipilimumab phase I trial treatment schedule. Dn, day n; Ipi, ipilimumab.
Clinical timelines for all patients, including comparative size-proportional pie-charts representing the number of antigens towards which antibody titers were detected. Timelines are separated by patients who did not develop high-grade irAEs (A) versus those who did (B).